Citations

Clear

2391 citation(s) found for "Ma, Lin".

Activation of FAK/Rac1/Cdc42‐GTPase signaling ameliorates impaired microglial migration response to Aβ 42 in triggering receptor expressed on myeloid cells 2 loss‐of‐function murine models
Rong, Zhouyi , Cheng, Baoying, Zhong, Li , Jia, Lin , Li, Yanfang , Shue, Francis , Wang, Na , Cheng, Yiyun , Huang, Xiaohua , Liu, Chia‐Chen , Fryer, John Denis , Wang, Xin , Zhang, Yun‐wu , Zheng, Honghua , Liu, Chia-Chen , Shue, Francis , Ye, Xiaowen , Li, Xin , Wang, Na

Mayo Clinic

The FASEB Journal | July 29, 2020 | Volume: 34 | Issue: 8 | Pages: 10984-10997

10.1096/fj.202000550rr | PMID 32613609 Get It

Abstract Mutation of Triggering receptor expressed on myeloid cells 2 (TREM2) impairs the response of microglia to amyloid‐β (Aβ) pathology in Alzheimer's disease (AD), although the mechanism governing TREM2‐regulated microglia recruitment to Aβ plaques remains unresolved. Here, we confirm that TREM2 mutation attenuates microglial migration. Then, using Trem2 −/− mice and an R47H variant mouse model for AD generated for this study, we show that TREM2 deficiency or the AD‐associated R47H mutation results in inhibition of FAK and Rac1/Cdc42‐GTPase signaling critical for cell migration. Intriguingly, treatment with CN04, a Rac1/Cdc42‐GTPase activator, partially enhances microglial migration in response to oligomeric Aβ 42 in Trem2 −/− or R47H microglia both in vitro and in vivo. Our study shows that the dysfunction of microglial migration in the AD‐associated TREM2 R47H variant is caused by FAK/Rac1/Cdc42 signaling disruption, and that activation of this signaling ameliorates impaired microglial migration response to Aβ 42 , suggesting a therapeutic target for R47H‐bearing patients with high risk of AD.
CRISPR/Cas9-mediated introduction of the sodium/iodide symporter gene enables noninvasive in vivo tracking of induced pluripotent stem cell-derived cardiomyocytes
Ostrominski, John W. , Yada, Ravi Chandra , Sato, Noriko , Klein, Michael G. , Blinova, Ksenia , Valadez, Racquel, Palisoc, Maryknoll, Peng, Kah-Whye , San, Hong, Lin, Yongshun, Basuli, Falguni , Swenson, Rolf E. , Haigney, Mark C. , Boehm, Manfred , Hong, So Gun , Hong, So Gun , Dunbar, Cynthia E , Patel, Dakshesh , Pittaluga, Stefania , Zhang, Xiang , Choyke, Peter L. , Zou, Jizhong

Mayo Clinic

Stem Cells Translational Medicine | July 23, 2020 | Volume: 9 | Issue: 10 | Pages: 1203-1217

10.1002/sctm.20-0019 | PMID 32700830 Get It

Abstract Techniques that enable longitudinal tracking of cell fate after myocardial delivery are imperative for optimizing the efficacy of cell-based cardiac therapies. However, these approaches have been underutilized in preclinical models and clinical trials, and there is considerable demand for site-specific strategies achieving long-term expression of reporter genes compatible with safe noninvasive imaging. In this study, the rhesus sodium/iodide symporter (NIS) gene was incorporated into rhesus macaque induced pluripotent stem cells (RhiPSCs) via CRISPR/Cas9. Cardiomyocytes derived from NIS-RhiPSCs (NIS-RhiPSC-CMs) exhibited overall similar morphological and electrophysiological characteristics compared to parental control RhiPSC-CMs at baseline and with exposure to physiological levels of sodium iodide. Mice were injected intramyocardially with 2 million NIS-RhiPSC-CMs immediately following myocardial infarction, and serial positron emission tomography/computed tomography was performed with 18F-tetrafluoroborate to monitor transplanted cells in vivo. NIS-RhiPSC-CMs could be detected until study conclusion at 8 to 10 weeks postinjection. This NIS-based molecular imaging platform, with optimal safety and sensitivity characteristics, is primed for translation into large-animal preclinical models and clinical trials.
Noninvasive assessment of liver fibrosis in chronic hepatitis B carriers with sound touch elastography: study of surgical pathology specimens
Li, Jiawu , Ma, Lin , Xiang, Hongjin , He, Du , Lu, Changli, Tang, Lin , Chen, Shigao , Yang, Lulu , Luo, Yan

Mayo Clinic

Expert Review of Medical Devices | July 18, 2020 | Volume: 17 | Issue: 8 | Pages: 845-853

10.1080/17434440.2020.1798226 | PMID 32686517 Get It

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
Shah, Nina , Aiello, Jack, Avigan, David , Borrello, Ivan , Chari, Ajai , Cohen, Adam D. , Ganapathi, Karthik A. , Gray, Lissa , Green, Damian, Krishnan, Amrita , Lin, Yi , Manasanch, Elisabet E. , Munshi, Nikhil C. , Rapoport, Aaron P. , Smith, Eric L. , Vij, Ravi , Dhodapkar, Madhav V. , Cohen, Adam D , Chari, Ajai , Lin, Yi , Berdeja, Jesús G. , Green, Damian J , Nooka, Ajay K.

Mayo Clinic

Journal for ImmunoTherapy of Cancer | July 13, 2020 | Volume: 8 | Issue: 2 | Pages: e000734

10.1136/jitc-2020-000734 | PMID 32661116 Get It

Outcomes in multiple myeloma (MM) have improved dramatically in the last two decades with the advent of novel therapies including immunomodulatory agents (IMiDs), proteasome inhibitors and monoclonal antibodies. In recent years, immunotherapy for the treatment of MM has advanced rapidly, with the approval of new targeted agents and monoclonal antibodies directed against myeloma cell-surface antigens, as well as maturing data from late stage trials of chimeric antigen receptor (CAR) T cells. Therapies that engage the immune system to treat myeloma offer significant clinical benefits with durable responses and manageable toxicity profiles, however, the appropriate use of these immunotherapy agents can present unique challenges for practicing physicians. Therefore, the Society for Immunotherapy of Cancer convened an expert panel, which met to consider the current role of approved and emerging immunotherapy agents in MM and provide guidance to the oncology community by developing consensus recommendations. As immunotherapy evolves as a therapeutic option for the treatment of MM, these guidelines will be updated.
Exploratory Genome-Wide Interaction Analysis of Nonsteroidal Anti-inflammatory Drugs and Predicted Gene Expression on Colorectal Cancer Risk
Petersen, Paneen S., Schmit, Stephanie L. , Drew, David A. , Berndt, Sonja I. , Brenner, Hermann , Casey, Graham , Chang‐Claude, Jenny , Gallinger, Steven , Gruber, Stephen B. , Haile, Robert W. , Harrison, Tabitha A. , Hoffmeister, Michael , Jacobs, Eric J. , Joshi, Amit D. , Li, Li , Lindor, Noralane M. , Martín, Vicente , Maclnnis, Robert J., Moreno, Vı́ctor , Nan, Hongmei , Rennert, Gad , Slattery, Martha L. , Thibodeau, S. N., Weinstein, Stephanie J. , Woods, Michael O. , Peters, Ulrike , Brenner, Hermann , Rennert, Gad , Drew, David A , Brenner, Hermann , Gruber, Stephen B , Haile, Robert W , Harrison, Tabitha A , Hoffmeister, Michael , Martín, Vicente , Milne, Roger L , Maclnnis, Robert , Moreno, Victor , Potter, John D , Rennert, Gad , Slattery, Martha L , Thibodeau, Steve N, Weinstein, Stephanie J , Rennert, Gad , Brenner, Hermann , Nan, Hongmei , Wang, Xiaoliang , Su, Yu-Ru , Bien, Stephanie A. , Albanes, Demetrius , Campbell, Peter T. , Jenkins, Mark A. , Lin, Yi , Marchand, Loı̈c Le , Milne, Roger L. , Newcomb, Polly A. , Potter, John D. , Chan, Andrew T. , White, Emily , Hsu, Li

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | July 10, 2020 | Volume: 29 | Issue: 9 | Pages: 1800-1808

10.1158/1055-9965.epi-19-1018 | PMID 32651213 Get It

Abstract Background: Regular use of nonsteroidal anti-inflammatory drugs (NSAID) is associated with lower risk of colorectal cancer. Genome-wide interaction analysis on single variants (G × E) has identified several SNPs that may interact with NSAIDs to confer colorectal cancer risk, but variations in gene expression levels may also modify the effect of NSAID use. Therefore, we tested interactions between NSAID use and predicted gene expression levels in relation to colorectal cancer risk. Methods: Genetically predicted gene expressions were tested for interaction with NSAID use on colorectal cancer risk among 19,258 colorectal cancer cases and 18,597 controls from 21 observational studies. A Mixed Score Test for Interactions (MiSTi) approach was used to jointly assess G × E effects which are modeled via fixed interaction effects of the weighted burden within each gene set (burden) and residual G × E effects (variance). A false discovery rate (FDR) at 0.2 was applied to correct for multiple testing. Results: Among the 4,840 genes tested, genetically predicted expression levels of four genes modified the effect of any NSAID use on colorectal cancer risk, including DPP10 (PG×E = 1.96 × 10−4), KRT16 (PG×E = 2.3 × 10−4), CD14 (PG×E = 9.38 × 10−4), and CYP27A1 (PG×E = 1.44 × 10−3). There was a significant interaction between expression level of RP11-89N17 and regular use of aspirin only on colorectal cancer risk (PG×E = 3.23 × 10−5). No interactions were observed between predicted gene expression and nonaspirin NSAID use at FDR < 0.2. Conclusions: By incorporating functional information, we discovered several novel genes that interacted with NSAID use. Impact: These findings provide preliminary support that could help understand the chemopreventive mechanisms of NSAIDs on colorectal cancer.
Response by Lin to Letter Regarding Article, “Collateral Recruitment Is Impaired by Cerebral Small Vessel Disease”
Lin, Michelle , Lin, Michelle P, Lin, Michelle P

Mayo Clinic

Stroke | July 10, 2020 | Volume: 51 | Issue: 8 | Pages: No page available

10.1161/strokeaha.120.030530 | PMID 32646334 Get It

Bedside Visualization of Heart-Lung Interactions by Speckle Tracking Echocardiography: A Tale of Two Hearts
Long, C., Moraes, Adriano, Lin, Guan‐Ling , Oeckler, Richard A. , Wiley, Brandon M.

Mayo Clinic

B25. MECHANICAL VENTILATION AND ARDS: CLINICAL AND PHYSIOLOGICAL STUDIES | July 7, 2020 | Volume: No volume available | Issue: No issue available | Pages: A2886-A2886

10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a2886 Get It

Ultrastructural Pathology of Neurofibrillary Tangles in Transgenic Mice Carrying Mutant (P301l) Human Tau Gene
Lin, W-L, Lewis, Jada , Corral, Anthony, Lin, W-L, Dickson, Dennis W. , Hutton, M.

Mayo Clinic

Microscopy and Microanalysis | July 2, 2020 | Volume: 6 | Issue: S2 | Pages: 584-585

10.1017/s1431927600035418 Get It

Abstract Tau is a microtubule-associated protein that promotes polymerization and stabilization of microtubules. It is the major component of fibrillary neuronal and glial inclusions in Alzheimer's disease (AD) and the tauopathies. An autosomal dominant familial tauopathy, frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17), has been shown to be caused by pathogenic tau mutations. Neuropathologic features of FTDP-17 are filamentous tau aggregates in neurons and glia. Previous transgenic mice carrying the normal human tau gene developed motor neuron disease and had dystrophic axons, but no neurofibrillary tangles (NFT). In this report we describe ultrastructural features of NFT in transgenic mice carrying a mutant human tau gene. The mice were generated with a tau cDNA containing exon 1, 4, 5, 7, 9, 10, 11-13, intron 13 and exon 14, driven by the mouse prion promoter (MoPrP) and containing the most common FTDP-17 mutation, P301L. The transgenic construct was generated by ligating the P301L tau cDNA with the mouse prion promoter.